Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cassava Sciences Inc (NQ: SAVA )

3.870 +0.040 (+1.04%)
Streaming Delayed Price Updated: 1:53 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cassava Sciences Inc

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
33 34 Next >
Better Buy: Biogen vs. Cassava Sciences
These two biotechs are going after a significant market: Alzheimer's. 
Via The Motley Fool
CASSAVA SHAREHOLDER ALERT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
Cassava Plummets — Again — After CEO Denies Data Manipulation Claims
Cassava CEO Remi Barbier denied allegations of data manipulation in the firm's Alzheimer's research on Friday. But SAVA stock tumbled, again. 
Via Investor's Business Daily
INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Cassava Sciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Cassava Sciences, Inc. (SAVA)
From Glancy Prongay & Murray LLP
Via Business Wire
Cassava CEO Goes Offensive Over Data Allegations
Cassava Sciences Inc (NASDAQ: SAVA) has garnered attention recently after a citizen petition with the FDA suggested that the use of Alzheimer's candidate data is based... 
Via Benzinga
Exposures Product Safety
INVESTOR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc. (SAVA) Investors
From Kirby McInerney LLP
Via Business Wire
Fraud Allegations Are Unlikely to Keep Cassava Stock Down
Cassava's unchallenged safety and cognition data will result in the FDA allowing it to conduct a Phase 3 trial. SAVA stock is a buy. 
Via InvestorPlace
Topics Fraud
Exposures Legal Product Safety
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Abbott Laboratories (NYSE:... 
Via Benzinga
CASSAVA SHAREHOLDER ALERT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Cassava Sciences, Inc. (SAVA)
From Law Offices of Howard G. Smith
Via Business Wire
Cassava Sciences Stock Will Fall Further on Data Manipulation Allegations
SAVA stock is still one of the best performers this year, but the recent allegations mean shares will fall further as the story develops. 
Via InvestorPlace
Here's How You Handle a Volatile Stock Like Cassava Sciences
Investing in biotech stocks can pay off big, but only if their research pans out. Pay attention to the risk-reward ratio -- and control your greed. 
Via The Motley Fool
Lawsuits Filed Against COIN, ATVI and SAVA - Jakubowitz Law Pursues Shareholders Claims
NEW YORK, NY / ACCESSWIRE / September 2, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies... 
From Jakubowitz Law
Via AccessWire
Topics Fraud Lawsuit
Exposures Financial Legal
CASSAVA DEADLINE ALERT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Neuronetics (NASDAQ:STIM) stock rose 16.51% to $7.83 during Wednesday's regular session. As of 12:30 EST, this security is trading at a volume of 675.7K shares... 
Via Benzinga
Lawsuits Filed Against PLL, KPLT and SAVA - Jakubowitz Law Pursues Shareholders Claims
NEW YORK, NY / ACCESSWIRE / September 1, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies... 
From Jakubowitz Law
Via AccessWire
Topics Fraud Lawsuit
Exposures Financial Legal
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of BLCT, LIVE and SAVA
NEW YORK, NY / ACCESSWIRE / September 1, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to... 
From The Klein Law Firm
Via AccessWire
Topics Fraud Lawsuit
Exposures Financial Legal
SAVA ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Cassava Sciences, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Case
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
SHAREHOLDER ALERT: Robbins LLP Announces that Cassava Sciences, Inc. (SAVA) is Being Sued for Misleading Shareholders
From Robbins LLP
Via Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc. (SAVA) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
CLASS ACTION UPDATE for ZY, ATIP and SAVA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / August 31, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies.... 
From Levi & Korsinsky, LLP
Via AccessWire
Topics Lawsuit
Exposures Financial Legal
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Cassava Sciences, Inc. (SAVA) Investors
From Law Offices of Howard G. Smith
Via Business Wire
Lawsuits Filed Against JRVR, SAVA and HYRE - Jakubowitz Law Pursues Shareholders Claims
NEW YORK, NY / ACCESSWIRE / August 31, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies... 
From Jakubowitz Law
Via AccessWire
Topics Fraud Lawsuit
Exposures Financial Legal
Wait to See How the Cassava Sciences Allegations Pan Out
Allegations have been leveled against Cassava Sciences. SAVA stock has fallen by more than 50% as a result. Is this a buy-on-the-dip moment? 
Via InvestorPlace
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of KPLT, SAVA and HYRE
NEW YORK, NY / ACCESSWIRE / August 31, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to... 
From The Klein Law Firm
Via AccessWire
Topics Fraud Lawsuit
Exposures Financial Legal
CASSAVA SCIENCES ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Cassava Sciences and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
CASSAVA DEADLINE ALERT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
SAVA CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Cassava Sciences, Inc.
From Glancy Prongay & Murray LLP
Via Business Wire
Insiders Like Cassava Sciences, Which Might Be Good News
Insider transactions have historically proven quite prescient for the trajectory of SAVA stock, so what do they imply today? 
Via InvestorPlace
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
33 34 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.